Mehra Golshan, MD, MBA

• Anees Chagpar
• Cary Gross
• Christin A. Knowlton
• Donald Lannin
• Elizabeth Berger
• Eric Winer
• Gregory Zanieski
• Ian Krop
• Lajos Pusztai
• Malini Harigopal
• Mariya Rozenblit
• Melinda Irwin
• Michael DiGiovanna
• Rachel Greenup
• Tristen Park

Breast

• Great Debate: The Surgeon’s Role in Locoregional Management of Stage IV Breast CancerLucci A, Kim L, Golshan M, King T. Great Debate: The Surgeon’s Role in Locoregional Management of Stage IV Breast Cancer. Annals Of Surgical Oncology 2023, 30: 7000-7007. PMID: 37596450, DOI: 10.1245/s10434-023-14134-7.
• Regional block pilot for microvascular free-flap breast reconstruction.Kim L, Long A, Miller J, Zurich H, Golshan M, Li J. Regional block pilot for microvascular free-flap breast reconstruction. Journal Of Clinical Oncology 2022, 40: e18646-e18646. DOI: 10.1200/jco.2022.40.16_suppl.e18646.
• Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trialGeyer C, Sikov W, Huober J, Rugo H, Wolmark N, O’Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo J, Metzger O, Dunbar M, Symmans W, Rastogi P, Sohn J, Young R, Wright G, Harkness C, McIntyre K, Yardley D, Loibl S. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals Of Oncology 2022, 33: 384-394. PMID: 35093516, DOI: 10.1016/j.annonc.2022.01.009.
• ASO Visual Abstract: Association of Medicaid Expansion on Postmastectomy Reconstruction RatesLe Blanc J, Golshan M, Lannin D, Greenup R, Berger E, Saridakis A, Horowitz N, Zanieski G, Avraham T, Mastrioanni M, Park T. ASO Visual Abstract: Association of Medicaid Expansion on Postmastectomy Reconstruction Rates. Annals Of Surgical Oncology 2022, 29: 2191-2192. DOI: 10.1245/s10434-021-10944-9.
• Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightnessMetzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O’Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE, Loibl S, Stover DG. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. Npj Breast Cancer 2021, 7: 142. PMID: 34764307, PMCID: PMC8586340, DOI: 10.1038/s41523-021-00349-y.
• ASO Author Reflections: Apocrine Breast Cancer: More Questions than AnswersSaridakis A, Berger ER, Greenup R, Golshan M, Lannin DR. ASO Author Reflections: Apocrine Breast Cancer: More Questions than Answers. Annals Of Surgical Oncology 2021, 29: 581-582. PMID: 34743280, DOI: 10.1245/s10434-021-10649-z.
• The Impact of COVID-19 on Breast Surgery FellowshipsFriedrich AU, DiComo JA, Golshan M. The Impact of COVID-19 on Breast Surgery Fellowships. Current Breast Cancer Reports 2021, 13: 235-240. PMID: 34703524, PMCID: PMC8531885, DOI: 10.1007/s12609-021-00430-2.
• Exploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgeryKnoerl R, Giobbie-Hurder A, Sannes TS, Chagpar AB, Dillon D, Dominici LS, Frank ES, Golshan M, McTiernan A, Rhei E, Tolaney SM, Winer EP, Yung RL, Irwin ML, Ligibel JA. Exploring the impact of exercise and mind–body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery. Supportive Care In Cancer 2021, 30: 2027-2036. PMID: 34648061, DOI: 10.1007/s00520-021-06617-8.
• ASO Visual Abstract: Cancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) ProgramPak L, Purad C, Nadipally S, Rao M, Mukherjee S, Hegde S, Golshan M. ASO Visual Abstract: Cancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) Program. Annals Of Surgical Oncology 2021, 28: 727-728. DOI: 10.1245/s10434-021-10470-8.
• Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgeryBasu SS, Stopka SA, Abdelmoula WM, Randall EC, Gimenez-Cassina Lopez B, Regan MS, Calligaris D, Lu FF, Norton I, Mallory MA, Santagata S, Dillon DA, Golshan M, Agar NYR. Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery. Npj Breast Cancer 2021, 7: 116. PMID: 34504095, PMCID: PMC8429658, DOI: 10.1038/s41523-021-00318-5.
• 119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trialLoibl S, Sikov W, Huober J, Rugo H, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo J, Metzger O, Dunbar M, Symmans W, Geyer C. 119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial. Annals Of Oncology 2021, 32: s408. DOI: 10.1016/j.annonc.2021.08.400.
• Surgical Management of Hereditary Breast CancerBerger ER, Golshan M. Surgical Management of Hereditary Breast Cancer. Genes 2021, 12: 1371. PMID: 34573353, PMCID: PMC8470490, DOI: 10.3390/genes12091371.
• Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast CancerSaridakis A, Berger ER, Harigopal M, Park T, Horowitz N, Le Blanc J, Zanieski G, Chagpar A, Greenup R, Golshan M, Lannin DR. Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer. Annals Of Surgical Oncology 2021, 28: 5610-5616. PMID: 34426884, DOI: 10.1245/s10434-021-10518-9.
• Correction to: Prediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain ModulatorsSchreiber KL, Zinboonyahgoon N, Mikayla Flowers K, Hruschak V, Fields KG, Patton ME, Schwartz E, Azizoddin D, Soens M, King T, Partridge A, Pusic A, Golshan M, Edwards RR. Correction to: Prediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain Modulators. Annals Of Surgical Oncology 2021, 28: 896-896. PMID: 34401990, DOI: 10.1245/s10434-021-10658-y.
• Immunotherapy Treatment for Triple Negative Breast CancerBerger ER, Park T, Saridakis A, Golshan M, Greenup RA, Ahuja N. Immunotherapy Treatment for Triple Negative Breast Cancer. Pharmaceuticals 2021, 14: 763. PMID: 34451860, PMCID: PMC8401402, DOI: 10.3390/ph14080763.
• Optimal Management for Residual Disease Following Neoadjuvant Systemic TherapyFoldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options In Oncology 2021, 22: 79. PMID: 34213636, DOI: 10.1007/s11864-021-00879-4.
• Cancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) ProgramPak LM, Purad CC, Nadipally S, Rao MP, Mukherjee S, Hegde SKB, Golshan M. Cancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) Program. Annals Of Surgical Oncology 2021, 28: 7006-7013. PMID: 34215953, DOI: 10.1245/s10434-021-10366-7.
• How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.
• ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)Weiss A, Campbell J, Ballman K, Sikov W, Carey L, Hwang E, Poppe M, Partridge A, Ollila D, Golshan M. ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Annals Of Surgical Oncology 2021, 28: 436-437. DOI: 10.1245/s10434-021-10005-1.
• ASO Author Reflections: Accurately Predicting Nodal pCR Holds the Key to Axillary Surgery De-escalation StrategiesWeiss A, Golshan M, Ollila DW. ASO Author Reflections: Accurately Predicting Nodal pCR Holds the Key to Axillary Surgery De-escalation Strategies. Annals Of Surgical Oncology 2021, 28: 5972-5973. PMID: 33851312, DOI: 10.1245/s10434-021-09953-5.
• Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)Weiss A, Campbell J, Ballman KV, Sikov WM, Carey LA, Hwang ES, Poppe MM, Partridge AH, Ollila DW, Golshan M. Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Annals Of Surgical Oncology 2021, 28: 5960-5971. PMID: 33821344, PMCID: PMC8532250, DOI: 10.1245/s10434-021-09897-w.
• Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast CancerFilho OM, Stover DG, Asad S, Ansell PJ, Watson M, Loibl S, Geyer CE, Bae J, Collier K, Cherian M, O’Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Symmans WF. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. JAMA Oncology 2021, 7: 603-608. PMID: 33599688, PMCID: PMC7893540, DOI: 10.1001/jamaoncol.2020.7310.
• Abstract OT-20-01: Genetic testing for all breast cancer patients (get facts)Weiss A, Braun D, Stopfer J, Desantis D, Dwan M, Davis D, Jha A, Dominici L, Rosenberg S, King T, Mittendorf E, Golshan M, Rana H, Garber J. Abstract OT-20-01: Genetic testing for all breast cancer patients (get facts). Cancer Research 2021, 81: ot-20-01-ot-20-01. DOI: 10.1158/1538-7445.sabcs20-ot-20-01.
• Prediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain ModulatorsSchreiber KL, Zinboonyahgoon N, Flowers KM, Hruschak V, Fields KG, Patton ME, Schwartz E, Azizoddin D, Soens M, King T, Partridge A, Pusic A, Golshan M, Edwards RR. Prediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain Modulators. Annals Of Surgical Oncology 2021, 28: 5015-5038. PMID: 33452600, PMCID: PMC8280248, DOI: 10.1245/s10434-020-09479-2.
• Survival Benefits Associated with Surgery in Patients with Metastatic Breast Cancer by Breast Cancer SubtypeHan H, . T, Yu J, Golshan M, Hsu H, Chu C, Hong Z, Fu C, Chou Y, Dai M, Liao G. Survival Benefits Associated with Surgery in Patients with Metastatic Breast Cancer by Breast Cancer Subtype. Journal Of Cancer Science And Clinical Therapeutics 2021, 05 DOI: 10.26502/jcsct.5079127.
• Omission of Surgical Axillary Lymph Node Staging in Patients with Tubular Breast CancerÖzkurt E, Wong S, Rhei E, Golshan M, Brock J, Barbie TU. Omission of Surgical Axillary Lymph Node Staging in Patients with Tubular Breast Cancer. Annals Of Surgical Oncology 2020, 28: 2589-2598. PMID: 33078312, DOI: 10.1245/s10434-020-09223-w.
• A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).Khan S, Zhao F, Solin L, Goldstein L, Cella D, Basik M, Golshan M, Julian T, Pockaj B, Lee C, Razaq W, Sparano J, Babiera G, Dy I, Jain S, Silverman P, Fisher C, Tevaarwerk A, Wagner L, Sledge G. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). Journal Of Clinical Oncology 2020, 38: lba2-lba2. DOI: 10.1200/jco.2020.38.18_suppl.lba2.
• The impact of pattern of tumor response and other post-treatment histologic features on local recurrence in patients treated with neoadjuvant chemotherapy and breast conservation.Laws A, Pastorello R, Choi J, Kantor O, Grossmith S, Schnitt S, Golshan M, Mittendorf E, King T. The impact of pattern of tumor response and other post-treatment histologic features on local recurrence in patients treated with neoadjuvant chemotherapy and breast conservation. Journal Of Clinical Oncology 2020, 38: 581-581. DOI: 10.1200/jco.2020.38.15_suppl.581.
• Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.Metzger Filho O, Stover D, Asad S, Ansell P, Watson M, Loibl S, Geyer C, O'Shaughnessy J, Untch M, Rugo H, Huober J, Golshan M, Sikov W, Von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Symmans W. Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study. Journal Of Clinical Oncology 2019, 37: 510-510. DOI: 10.1200/jco.2019.37.15_suppl.510.
• CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).Sikov W, Polley M, Twohy E, Perou C, Singh B, Berry D, Tolaney S, Somlo G, Port E, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon J, Collyar D, Hahn O, Hudis C, Winer E, Partridge A, Carey L. CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2019, 37: 591-591. DOI: 10.1200/jco.2019.37.15_suppl.591.
• Abstract P1-08-12: Trends in incidence of bilateral breast cancer: A Population-based comparative study of the United States and JapanSakai T, Ozkurt E, Desantis S, Wong S, Rosenbaum L, Zheng H, Ohno S, Golshan M. Abstract P1-08-12: Trends in incidence of bilateral breast cancer: A Population-based comparative study of the United States and Japan. Cancer Research 2019, 79: p1-08-12-p1-08-12. DOI: 10.1158/1538-7445.sabcs18-p1-08-12.
• Magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancerGolshan M, Wong S, Loibl S, Huober J, O'Shaughnessy J, Rugo H, Wolmark N, McKee M, Maag D, Sullivan D, Metzger-Filho O, Von Minckwitz G, Geyer C, Sikov W, Untch M. Magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer. European Journal Of Surgical Oncology 2019, 45: e12-e13. DOI: 10.1016/j.ejso.2018.10.075.
• Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.Telli M, Metzger O, Timms K, Evans B, Vogel D, Wei H, Jones J, Wenstrup R, McKee M, Sullivan D, Fallstrom M, Maag D, Ansell P, Sohn J, Chen S, Martinez N, Geyer C, Loibl S, Golshan M. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. Journal Of Clinical Oncology 2018, 36: 519-519. DOI: 10.1200/jco.2018.36.15_suppl.519.
• 25 Examination Techniques Roles of the Physician and Patient in Evaluating Breast DiseaseMallory M, Golshan M. 25 Examination Techniques Roles of the Physician and Patient in Evaluating Breast Disease. 2018, 331-336.e2. DOI: 10.1016/b978-0-323-35955-9.00025-8.
• Prognostic role of lymphovascular invasion and lymph node status among breast cancer subtypesLiao G, Hsu H, Chu C, Hong Z, Fu C, Chou Y, Golshan M, Dai M, Chen T, De-Chian C, Tsai W, Pan C, Hsu K, Kao E, Hsu Y, Chang T, Yu J. Prognostic role of lymphovascular invasion and lymph node status among breast cancer subtypes. Journal Of Medical Sciences 2018, 38: 54-61. DOI: 10.4103/jmedsci.jmedsci_105_17.
• 170P Impact of neoadjuvant therapy (NT) and pathological complete response (pCR) on breast-conserving surgery (BCS) in patients (pts) with breast cancer (BC): A meta-analysisCriscitiello C, Golshan M, Barry W, Viale G, Wong S, Santangelo M, Curigliano G. 170P Impact of neoadjuvant therapy (NT) and pathological complete response (pCR) on breast-conserving surgery (BCS) in patients (pts) with breast cancer (BC): A meta-analysis. Annals Of Oncology 2017, 28: v50-v51. DOI: 10.1093/annonc/mdx362.020.
• Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess).Golshan M, Loibl S, Huober J, O'Shaughnessy J, Rugo H, Wolmark N, McKee M, Maag D, Sullivan D, Giranda V, Liu X, Von Minckwitz G, Geyer C, Sikov W, Untch M. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess). Journal Of Clinical Oncology 2017, 35: 514-514. DOI: 10.1200/jco.2017.35.15_suppl.514.
• Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).Geyer C, O'Shaughnessy J, Untch M, Sikov W, Rugo H, McKee M, Huober J, Golshan M, Giranda V, Von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo J, Metzger Filho O, Rastogi P, Symmans W, Liu X, Loibl S. Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2017, 35: 520-520. DOI: 10.1200/jco.2017.35.15_suppl.520.
• Implementation of surgeon-initiated Oncotype DX ordering among patients with breast cancer to reduce chemotherapy wait times.Losk K, Freedman R, Lin N, Golshan M, Lester S, Pochebit S, Natsuhara K, Camuso K, King T, Bunnell C. Implementation of surgeon-initiated Oncotype DX ordering among patients with breast cancer to reduce chemotherapy wait times. Journal Of Clinical Oncology 2017, 35: 166-166. DOI: 10.1200/jco.2017.35.8_suppl.166.
• Label-free biomolecular characterization of human breast cancer tissue with stimulated Raman scattering (SRS) spectral imaging (Conference Presentation)Lu F, Calligaris D, Suo Y, Santagata S, Golby A, Xie X, Mallory M, Golshan M, Dillon D, Agar N. Label-free biomolecular characterization of human breast cancer tissue with stimulated Raman scattering (SRS) spectral imaging (Conference Presentation). Proceedings Of SPIE--the International Society For Optical Engineering 2017, 100690r-100690r-1. DOI: 10.1117/12.2253366.
• Abstract P5-11-02: Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancerLigibel J, Giobbie-Hurder A, Dillion D, Shockro L, Campbell N, Rhei E, Troyan S, Dominici L, Golshan M, Chagpar A, Yung R, Freedman R, Tolaney S, Winer E, Frank E, McTiernan A, Irwin M. Abstract P5-11-02: Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer. Cancer Research 2017, 77: p5-11-02-p5-11-02. DOI: 10.1158/1538-7445.sabcs16-p5-11-02.
• Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?Criscitiello C, Curigliano G, Burstein H, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? European Journal Of Surgical Oncology 2016, 42: 1780-1786. PMID: 27825710, DOI: 10.1016/j.ejso.2016.10.011.
• Management of lobular carcinoma in situ: A decision analysis.Wong S, Stout N, Punglia R, Golshan M. Management of lobular carcinoma in situ: A decision analysis. Journal Of Clinical Oncology 2016, 34: 1048-1048. DOI: 10.1200/jco.2016.34.15_suppl.1048.
• Abstract P1-12-08: Factors associated with delays in chemotherapy initiation among patients with breast cancerLosk K, Vaz Duarte Luis I, Camuso K, Lloyd M, Kadish S, Hirshfield-Bartek J, Cutone L, Golshan M, Lin N, Bunnell C. Abstract P1-12-08: Factors associated with delays in chemotherapy initiation among patients with breast cancer. Cancer Research 2016, 76: p1-12-08-p1-12-08. DOI: 10.1158/1538-7445.sabcs15-p1-12-08.
• Abstract P2-13-12: Implementation of a breast/reconstructive surgery coordinator to reduce preoperative delays for patients undergoing mastectomy with immediate reconstructionLosk K, Mallory M, Caterson S, Camuso K, Cutone L, Roberts P, Lin N, Bunnell C, Golshan M. Abstract P2-13-12: Implementation of a breast/reconstructive surgery coordinator to reduce preoperative delays for patients undergoing mastectomy with immediate reconstruction. Cancer Research 2016, 76: p2-13-12-p2-13-12. DOI: 10.1158/1538-7445.sabcs15-p2-13-12.
• Abstract P3-12-02: Patient prognostic score and survival benefit offered by radiotherapy for ductal carcinoma in situSagara Y, Freedman R, Vaz-Luis I, Mallory M, Wong S, Aydogan F, DeSantis S, Barry W, Golshan M. Abstract P3-12-02: Patient prognostic score and survival benefit offered by radiotherapy for ductal carcinoma in situ. Cancer Research 2016, 76: p3-12-02-p3-12-02. DOI: 10.1158/1538-7445.sabcs15-p3-12-02.
• Abstract S3-06: Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging: Results of a secondary analysis of TBCRC 017Hyslop T, Alvarado M, Forero A, Golshan M, Hieken T, Horton J, Hudis C, McGuire K, Meric-Bernstam F, Nanda R, Zagar T, Hwang S. Abstract S3-06: Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging: Results of a secondary analysis of TBCRC 017. Cancer Research 2016, 76: s3-06-s3-06. DOI: 10.1158/1538-7445.sabcs15-s3-06.
• Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)Sikov W, Berry D, Perou C, Singh B, Cirrincione C, Tolaney S, Somlo G, Port E, Qamar R, Sturtz K, Mamounas E, Golshan M, Bellon J, Collyar D, Hahn O, Carey L, Hudis C, Winer E. Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance). Cancer Research 2016, 76: s2-05-s2-05. DOI: 10.1158/1538-7445.sabcs15-s2-05.
• Tumor subtype and race in male breast cancer: A population-based cohort study.Aydogan F, Sagara Y, Mallory M, Tukenmez M, Golshan M. Tumor subtype and race in male breast cancer: A population-based cohort study. Journal Of Clinical Oncology 2015, 33: 149-149. DOI: 10.1200/jco.2015.33.28_suppl.149.
• Does “two is better than one” apply to surgeons? Comparing single-surgeon and cosurgeon bilateral mastectomy outcomes.Nimbkar S, Mallory M, Losk K, Camuso K, Golshan M. Does “two is better than one” apply to surgeons? Comparing single-surgeon and cosurgeon bilateral mastectomy outcomes. Journal Of Clinical Oncology 2015, 33: 35-35. DOI: 10.1200/jco.2015.33.28_suppl.35.
• Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?Criscitiello C, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? European Journal Of Surgical Oncology 2015, 41: 1288-1292. PMID: 26238477, DOI: 10.1016/j.ejso.2015.07.013.
• The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast.Sagara Y, Barry W, Mallory M, Wong S, Aydogan F, DeSantis S, Golshan M. The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast. Journal Of Clinical Oncology 2015, 33: 1006-1006. DOI: 10.1200/jco.2015.33.15_suppl.1006.
• Risk of axillary node metastasis in Paget disease with invasive ductal carcinoma.Wong S, Freedman R, Stamell E, Sagara Y, Brock J, DeSantis S, Golshan M. Risk of axillary node metastasis in Paget disease with invasive ductal carcinoma. Journal Of Clinical Oncology 2015, 33: 1054-1054. DOI: 10.1200/jco.2015.33.15_suppl.1054.
• Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance).Golshan M, Cirrincione C, Carey L, Sikov W, Berry D, Burstein H, Overmoyer B, Henry N, Somlo G, Port E, Winer E, Hudis C, Ollila D. Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance). Journal Of Clinical Oncology 2015, 33: 1007-1007. DOI: 10.1200/jco.2015.33.15_suppl.1007.
• Variation in the use of granulocyte-colony stimulating factor (G-CSF) for dose dense paclitaxel: A single institution retrospective study.Paes F, Luis I, Costa R, Metzger Filho O, Hughes M, Losk K, Camuso K, Bunnell C, Golshan M, Winer E, Lin N. Variation in the use of granulocyte-colony stimulating factor (G-CSF) for dose dense paclitaxel: A single institution retrospective study. Journal Of Clinical Oncology 2015, 33: 561-561. DOI: 10.1200/jco.2015.33.15_suppl.561.
• Bilateral Synchronous Benign Phyllodes TumorsMallory MA, Golshan M, Chikarmane S, Raza S, Lester S, Caterson S. Bilateral Synchronous Benign Phyllodes Tumors. The American Surgeon 2015, 81: 192-194. PMID: 25975306, PMCID: PMC4477195, DOI: 10.1177/000313481508100503.
• Abstract ES1-2: Reconstruction for the high risk patient: challenges of chemotherapy, radiation therapy and patient selectionGolshan M. Abstract ES1-2: Reconstruction for the high risk patient: challenges of chemotherapy, radiation therapy and patient selection. 2015, es1-2-es1-2. DOI: 10.1158/1538-7445.sabcs14-es1-2.
• Abstract P1-16-01: Effect of margin width on local recurrence in invasive lobular carcinoma treated with multimodality therapySagara Y, Barry W, Vaz-Luis I, Aydogan F, Brock J, Winer E, Golshan M, Metzger-Filho O. Abstract P1-16-01: Effect of margin width on local recurrence in invasive lobular carcinoma treated with multimodality therapy. 2015, p1-16-01-p1-16-01. DOI: 10.1158/1538-7445.sabcs14-p1-16-01.
• Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (AlliancSikov W, Barry W, Hoadley K, Pitcher B, Singh B, Tolaney S, Kuzma C, Pluard T, Somlo G, Port E, Golshan M, Berry D, Hahn O, Carey L, Perou C, Hudis C, Winer E. Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc. 2015, s4-05-s4-05. DOI: 10.1158/1538-7445.sabcs14-s4-05.
• Neoadjuvant Chemotherapy for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database Killelea BK, Yang VQ, Mougalian S, et al (Yale Univ School of Medicine, New Haven, CT) J Am Coll Surg 220:1063-1069, 2015§Nakhlis F, Golshan M. Neoadjuvant Chemotherapy for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database Killelea BK, Yang VQ, Mougalian S, et al (Yale Univ School of Medicine, New Haven, CT) J Am Coll Surg 220:1063-1069, 2015§. Breast Diseases A Year Book Quarterly 2015, 26: 334-335. DOI: 10.1016/j.breastdis.2015.10.030.
• Standardizing coordination between surgical oncology and reconstructive surgery for breast cancer patients undergoing mastectomy with immediate reconstruction.Golshan M, Hergrueter C, Camuso K, Lin N, Cutone L, Hirshfield-Bartek J, Roberts P, Runkle W, Kadish S, Losk K, Bunnell C. Standardizing coordination between surgical oncology and reconstructive surgery for breast cancer patients undergoing mastectomy with immediate reconstruction. Journal Of Clinical Oncology 2014, 32: 110-110. DOI: 10.1200/jco.2014.32.30_suppl.110.
• Genetic Predisposition to Breast CancerGolshan M. Genetic Predisposition to Breast Cancer. 2014, 263-264. DOI: 10.1007/978-1-4939-1565-1_66.
• Change in breast density as a response to adjuvant endocrine treatment: An American cohort.Wexelman B, Sagara Y, Min H, Raza S, Aydogan F, Golshan M. Change in breast density as a response to adjuvant endocrine treatment: An American cohort. Journal Of Clinical Oncology 2014, 32: e11523-e11523. DOI: 10.1200/jco.2014.32.15_suppl.e11523.
• Early PT Education for Pre-surgical Breast Cancer Survivors - A Preliminary Pilot StudyFlores A, Stephenson R, Golshan M, Lovitiz N, Marques A, Taber M, Weinandy M. Early PT Education for Pre-surgical Breast Cancer Survivors - A Preliminary Pilot Study. Rehabilitation Oncology 2014, 32: 38. DOI: 10.1097/01893697-201432020-00022.
• Abstract P1-01-04: Nodal patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy: Results of a secondary analysis of TBCRC 017McGuire K, De Los Santos J, Cantor A, Forero A, Golshan M, Meric-Bernstam F, Horton J, Amos K, Hudis C, Hylton N, Meszoely I, Nanda R, Hwang S. Abstract P1-01-04: Nodal patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy: Results of a secondary analysis of TBCRC 017. Cancer Research 2013, 73: p1-01-04-p1-01-04. DOI: 10.1158/0008-5472.sabcs13-p1-01-04.
• Abstract P5-13-15: Process-of-care: Elucidating delays in surgical treatment of breast cancerGolshan M, Weingart S, Losk K, Hirshfield-Bartek J, Cutone L, Abeita J, Kadish S, Bunnell C. Abstract P5-13-15: Process-of-care: Elucidating delays in surgical treatment of breast cancer. Cancer Research 2013, 73: p5-13-15-p5-13-15. DOI: 10.1158/0008-5472.sabcs13-p5-13-15.
• Abstract P6-12-05: The impact of residual disease after preoperative systemic therapy on clinical outcomes in patients with inflammatory breast cancerNakhlis F, Regan M, Warren L, Bellon J, Yeh E, Jacene H, Golshan M, Duggan M, Dominici L, Hirshfield-Bartek J, Mullaney E, Overmoyer B. Abstract P6-12-05: The impact of residual disease after preoperative systemic therapy on clinical outcomes in patients with inflammatory breast cancer. Cancer Research 2013, 73: p6-12-05-p6-12-05. DOI: 10.1158/0008-5472.sabcs13-p6-12-05.
• Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)Sikov W, Berry D, Perou C, Singh B, Cirrincione C, Tolaney S, Kuzma C, Pluard T, Somlo G, Port E, Golshan M, Bellon J, Collyar D, Hahn O, Carey L, Hudis C, Winer E. Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Cancer Research 2013, 73: s5-01-s5-01. DOI: 10.1158/0008-5472.sabcs13-s5-01.
• Magnetic Resonance Imaging-Guided Breast Intervention and SurgeryGombos E, Kacher D, Caragacianu D, Jayender J, Golshan M. Magnetic Resonance Imaging-Guided Breast Intervention and Surgery. 2013, 817-844. DOI: 10.1007/978-1-4614-7657-3_62.
• Reducing breast cancer chemotherapy treatment delays by improving the transition from surgical to medical oncology.Losk K, Kadish S, Golshan M, Lin N, Hirshfield-Bartek J, Cutone L, Bunnell C, Weingart S. Reducing breast cancer chemotherapy treatment delays by improving the transition from surgical to medical oncology. Journal Of Clinical Oncology 2013, 31: 51-51. DOI: 10.1200/jco.2013.31.31_suppl.51.
• Distinctive lipid profiles of human breast cancer and adjacent normal tissues by desorption electrospray ionization mass spectrometry imaging.Caragacianu D, Liu X, Norton I, Ide J, Richardson A, Dillon D, Jolesz F, Golshan M, Agar N. Distinctive lipid profiles of human breast cancer and adjacent normal tissues by desorption electrospray ionization mass spectrometry imaging. Journal Of Clinical Oncology 2013, 31: 1132-1132. DOI: 10.1200/jco.2013.31.15_suppl.1132.
• Neoadjuvant bevacizumab: Surgical complications of mastectomy with and without reconstruction.Kansal K, Dominici L, Tolaney S, Isakoff S, Krop I, Smith B, Jiang W, Potler H, Brock J, Winer E, Golshan M. Neoadjuvant bevacizumab: Surgical complications of mastectomy with and without reconstruction. Journal Of Clinical Oncology 2013, 31: 1100-1100. DOI: 10.1200/jco.2013.31.15_suppl.1100.
• Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance).Ollila D, Berry D, Cirrincione C, Carey L, Amos K, Henry N, Winer E, Hudis C, Golshan M. Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance). Journal Of Clinical Oncology 2013, 31: 501-501. DOI: 10.1200/jco.2013.31.15_suppl.501.
• Management of the axilla IIDominici L, Golshan M. Management of the axilla II. 2013, 441-446. DOI: 10.1201/b13937-44.
• Skin-sparing forms of mastectomyDominici L, Golshan M. Skin-sparing forms of mastectomy. 2013, 387-402. DOI: 10.1201/b13937-41.
• Application of ACOSOG Z0011 Criteria Reduces Perioperative Costs Camp MS, Greenup RA, Taghian A, et al (Massachusetts General Hosp, Boston) Ann Surg Oncol 20:836-841, 2013§Nakhlis F, Golshan M. Application of ACOSOG Z0011 Criteria Reduces Perioperative Costs Camp MS, Greenup RA, Taghian A, et al (Massachusetts General Hosp, Boston) Ann Surg Oncol 20:836-841, 2013§. Breast Diseases A Year Book Quarterly 2013, 24: 361-362. DOI: 10.1016/j.breastdis.2013.10.037.
• Safety of bevacizumab in metastatic breast cancer patients undergoing surgery Cortés J, Caralt M, Delaloge S, et al (Vall d'Hebron Univ Hosp, Barcelona, Spain; Institut Gustave Roussy, Villejuif Cedex, France; et al) Eur J Cancer 48:475-481, 2012§Dominici L, Golshan M. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery Cortés J, Caralt M, Delaloge S, et al (Vall d'Hebron Univ Hosp, Barcelona, Spain; Institut Gustave Roussy, Villejuif Cedex, France; et al) Eur J Cancer 48:475-481, 2012§. Breast Diseases A Year Book Quarterly 2012, 23: 351-352. DOI: 10.1016/j.breastdis.2012.09.015.
• P2-08-02: Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated with Neoadjuvant Systemic Treatment for Operable Breast Cancer (TBCRC 017).De L, Cantor A, Mcguire K, Golshan M, Meric-Bernstam F, Horton J, Nanda R, Amos K, Forero A, Hudis C, Meszoely I, Hwang S. P2-08-02: Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated with Neoadjuvant Systemic Treatment for Operable Breast Cancer (TBCRC 017). Cancer Research 2011, 71: p2-08-02-p2-08-02. DOI: 10.1158/0008-5472.sabcs11-p2-08-02.
• P2-15-01: Surgical Patterns of Care after Magnetic Resonance Imaging in the Academic Setting in Patients with Operable Breast Cancer Treated with Neoadjuvant Systemic Therapy: A Secondary Analysis of TBCRC 017.De L, Cantor A, Mcguire K, Golshan M, Meric-Bernstam F, Horton J, Nanda R, Amos K, Forero A, Hudis C, Meszoely I, Hwang S. P2-15-01: Surgical Patterns of Care after Magnetic Resonance Imaging in the Academic Setting in Patients with Operable Breast Cancer Treated with Neoadjuvant Systemic Therapy: A Secondary Analysis of TBCRC 017. Cancer Research 2011, 71: p2-15-01-p2-15-01. DOI: 10.1158/0008-5472.sabcs11-p2-15-01.
• Surgical Margins and the Risk of Local-Regional Recurrence (LRR) following Mastectomy for Early-stage Breast CancerChilds S, Chen Y, Golshan M, Duggan M, Pochebit S, Wong J, Harris J, Bellon J. Surgical Margins and the Risk of Local-Regional Recurrence (LRR) following Mastectomy for Early-stage Breast Cancer. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s233-s234. DOI: 10.1016/j.ijrobp.2011.06.436.
• Surgical margins and the risk of local-regional recurrence (LRR) following mastectomy for early-stage breast cancer.Childs S, Chen Y, Pochebit S, Golshan M, Duggan M, Wong J, Harris J, Bellon J. Surgical margins and the risk of local-regional recurrence (LRR) following mastectomy for early-stage breast cancer. Journal Of Clinical Oncology 2011, 29: 95-95. DOI: 10.1200/jco.2011.29.27_suppl.95.
• Use of intraoperative digital specimen mammography to improve operative efficiency.Valero M, Dominici L, Golshan M. Use of intraoperative digital specimen mammography to improve operative efficiency. Journal Of Clinical Oncology 2011, 29: 138-138. DOI: 10.1200/jco.2011.29.27_suppl.138.
• Can axillary lymph node dissection be omitted in patients with breast cancer and positive sentinel nodes?Dominici L, Golshan M. Can axillary lymph node dissection be omitted in patients with breast cancer and positive sentinel nodes? Minerva Surgery 2010, 65: 547-54. PMID: 21081866.
• Impact of neoadjuvant chemotherapy on breast reconstruction.Hu Y, Weeks C, In H, Dodgion C, Golshan M, Chun Y, Hassett M, Gu X, Lipsitz S, Greenberg C. Impact of neoadjuvant chemotherapy on breast reconstruction. Journal Of Clinical Oncology 2010, 28: 6135-6135. DOI: 10.1200/jco.2010.28.15_suppl.6135.
• Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer.Sikov W, Perou C, Golshan M, Collyar D, Berry D, Hahn O, Singh B, Hudis C, Winer E. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. Journal Of Clinical Oncology 2010, 28: tps110-tps110. DOI: 10.1200/jco.2010.28.15_suppl.tps110.
• Surgical Complications and the Use of Neoadjuvant Bevacizumab.Golshan M, Garber J, Gelman R, Tung N, Smith B, Troyan S, Greenberg C, Winer E, Ryan P. Surgical Complications and the Use of Neoadjuvant Bevacizumab. Cancer Research 2009, 69: 43-43. DOI: 10.1158/0008-5472.sabcs-09-43.
• Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacyRyan P, Tung N, Isakoff S, Golshan M, Richardson A, Corben A, Smith B, Gelman R, Winer E, Garber J. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. Journal Of Clinical Oncology 2009, 27: 551-551. DOI: 10.1200/jco.2009.27.15_suppl.551.
• Factors affecting surgical decision-making in patients undergoing BRCA1/2 testing at breast cancer diagnosis.Stadler Z, Stoeckert K, Perez A, Regan M, Golshan M, Garber J. Factors affecting surgical decision-making in patients undergoing BRCA1/2 testing at breast cancer diagnosis. Cancer Research 2009, 69: 1095. DOI: 10.1158/0008-5472.sabcs-1095.
• Chapter 35 Examination Techniques Roles of the Physician and Patient in Evaluating Breast DiseaseGolshan M. Chapter 35 Examination Techniques Roles of the Physician and Patient in Evaluating Breast Disease. 2009, 605-611. DOI: 10.1016/b978-1-4160-5221-0.00035-8.
• Matched Pair Analyses of Stage IV Breast Cancer with or Without Resection of Primary Breast SiteCady B, Nathan N, Michaelson J, Golshan M, Smith B. Matched Pair Analyses of Stage IV Breast Cancer with or Without Resection of Primary Breast Site. Annals Of Surgical Oncology 2008, 15: 3384-3395. PMID: 18726129, DOI: 10.1245/s10434-008-0085-x.
• American Society of Breast Disease Policy Statement on The Use of Breast Magnetic Resonance ImagingCommittee A, Harms S, Early A, Bevers T, Giuliano A, Golshan M, Hertz I, Kiel K, Kivitz P, Leitch A, Overmoyer B, Vargas H, Silva E, Siziopikou K, Shriver C, Olopade O. American Society of Breast Disease Policy Statement on The Use of Breast Magnetic Resonance Imaging. Seminars In Breast Disease 2008, 11: 111-112. DOI: 10.1053/j.sembd.2008.06.001.
• Young Breast Cancer Patients Undergoing Breast-Conserving Therapy: Role of BRCA1 and BRCA2Bafford A, Garber J, Chittenden A, Golshan M. Young Breast Cancer Patients Undergoing Breast-Conserving Therapy: Role of BRCA1 and BRCA2. 2008, 1: 483-491. DOI: 10.1007/978-1-4020-8369-3_33.
• Breast PainGolshan M. Breast Pain. 2008, 345-346. DOI: 10.1007/978-0-387-75246-4_85.
• Invasive Breast CancerGolshan M. Invasive Breast Cancer. 2008, 337-339. DOI: 10.1007/978-0-387-75246-4_83.
• 11 Factors Associated With Involvement of Four or More Axillary Nodes for Sentinel Lymph Node Positive PatientsKatz A, Smith B, Golshan M, Niemierko A, Kobayashi W, Gadd M, Specht M, Rizk L, Kelada A, Taghian A. 11 Factors Associated With Involvement of Four or More Axillary Nodes for Sentinel Lymph Node Positive Patients. International Journal Of Radiation Oncology • Biology • Physics 2006, 66: s6-s7. DOI: 10.1016/j.ijrobp.2006.07.025.
• Preclinical breast MRI findings in inflammatory breast carcinomaNakhlis F, Duggan M, Golshan M, Levin E. Preclinical breast MRI findings in inflammatory breast carcinoma. Journal Of Clinical Oncology 2005, 23: 899-899. DOI: 10.1200/jco.2005.23.16_suppl.899.
• Prediction of breast cancer size by ultrasound, mammography and core biopsyGolshan M, Fung B, Wiley E, Wolfman J, Rademaker A, Morrow M. Prediction of breast cancer size by ultrasound, mammography and core biopsy. The Breast 2004, 13: 265-271. PMID: 15325659, DOI: 10.1016/j.breast.2004.05.005.
• The effect of ipsilateral whole breast ultrasonography on the surgical management of breast carcinomaGolshan M, Fung B, Wolfman J, Rademaker A, Morrow M. The effect of ipsilateral whole breast ultrasonography on the surgical management of breast carcinoma. The American Journal Of Surgery 2003, 186: 391-396. PMID: 14553857, DOI: 10.1016/s0002-9610(03)00280-0.
• Sentinel Lymph Node Biopsy Lowers the Rate of Lymphedema When Compared with Standard Axillary Lymph Node DissectionGolshan M, Martin W, Dowlatshahi K. Sentinel Lymph Node Biopsy Lowers the Rate of Lymphedema When Compared with Standard Axillary Lymph Node Dissection. The American Surgeon 2003, 69: 209-212. PMID: 12678476, DOI: 10.1177/000313480306900306.
• Exploration for multiglandular disease in primary hyperparathyroidismGolshan M, Lotfi P, Prinz R. Exploration for multiglandular disease in primary hyperparathyroidism. Operative Techniques In General Surgery 1999, 1: 85-94. DOI: 10.1016/s1524-153x(99)80010-4.